In Stock

Beckman Coulter 33200 Access CEA Reagent, 100 determinations

$482.00

Analyzer Series: Access Analyzer Series
Brand: Beckman Coulter
Manufacturer SKU: 33200
Package Size: 2 x 50 Tests
Test Type: Tumor Marker Assay
Test Name: Carcinoembryonic Antigen
Analyzer Type: Hematology Analayzer
SKU: 33200 Category:

Description

Beckman Coulter 33200 Access CEA Reagent Specifications:

  • Brand: Access
  • Manufacturer: Beckman Coulter 33200
  • Country of Origin: France
  • Application: CEA Reagent
  • For Use With: For use with Access Immunoassay Systems
  • Number of Tests: 2 X 50 Tests
  • Test Name: Carcinoembryonic Antigen
  • Test Type: Tumor Marker Assay
INTENDED USE: Beckman Coulter 33200 Access CEA Reagent

Using the Access CEA Reagent, the Access CEA assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of Carcinoembryonic Antigen (CEA) levels in human serum, using the Access Immunoassay Systems. CEA measured by the Access Immunoassay Systems is used as an aid in the management of cancer patients in whom changing CEA concentrations have been observed.

SUMMARY AND EXPLANATION: Beckman Coulter 33200 Access CEA Reagent

Carcinoembryonic antigen (CEA), first described by Gold and Freedman in 1965, was isolated from extracts of liver metastases of colon adenocarcinomas and normal fetal digestive tract. It is considered one of the most extensively investigated human tumor associated antigens. An immunologically heterogenous group of glycoproteins, CEA is Instructions For Use A33769 U English Access CEA MAY 2020 Page 1 of 12 approximately 200,000 daltons with 50-85% carbohydrates by weight.

Access CEA Reagent is a member of the immunoglobulin superfamily and appears to have functions of an intercellular adhesion molecule. In addition, molecules structurally related to CEA (i.e. NCA, NCA-2, NFA) have been reported in normal adult tissues.

The measurement of serum CEA has shown substantial benefit in the prognosis and management of patients with malignant diseases, especially colorectal cancer. Serial measurements can be used to monitor patients for progression, regression or recurrence of cancer following treatment. A persistent elevation of CEA following therapeutic or surgical intervention signals residual disease or recurrence, whereas decreasing levels to within the normal range is indicative of successful intervention.

CEA is also elevated in the serum of patients with non-malignant diseases and in heavy smokers, therefore CEA should not be used in the diagnosis of cancer or for screening asymptomatic patients.